>
Everything I Warned You About Just Happened... All in One Week
Your Grief, My Grief, Our Grief in the Loss of a Loved One
Vance: Federal Government Has Identified $230 Billion In Fraud Since March
Saudi Arabia's $5 Oil Detour Is Expensive... But Worth It
What could possibly go wrong? Scientists use AI to design new viruses
Dual-motor suitcase drive underpins 3,000-hp hypercar
DoorDash Wins Federal Approval To Fly Its Own Delivery Drones
Shade-Resistant Solar Cells Retain 97% Efficiency After 2,000 Hours of Testing
20 Ancient Engineering SECRETS
Stonehenge Was Reanalyzed by AI -- And the Findings Are Hard to Explain
After Years Of Delays, Aptera Is Finally Preparing To Build Customer Cars
'When you kill it, it doesn't die': the jellyfish that has cracked the secret of immorta
Archer Aviation debuts Halo autonomous VTOL, Thunder's commercial twin
US Telecoms Slide On Starlink Mobile Threat; Bernstein Sees It As A "Jab, But No Knockout Yet**

Now an international team of researchers has, for the first time, successfully synthesized the compound and used it to treat a bacterial infection in mice. This is an important milestone in the quest to develop a new antibiotic in the war against antibiotic-resistant superbugs.
"When teixobactin was discovered it was groundbreaking in itself as a new antibiotic which kills bacteria without detectable resistance including superbugs such as MRSA, but natural teixobactin was not created for human use," explains Ishwar Singh, one of the scientists involved in the new research.
Late last year, a University of Lincoln team revealed it had successfully developed a synthesized version of teixobactin, with an easier synthesis process speeding up a single coupling step from 30 hours to just 10 minutes. At the time, the potency of the new synthesized drug was only demonstrated in vitro.